Chester County News and Community Website
WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) will participate in the Chardan 10th Annual Healthcare Conference on October 20, giving investors an opportunity to hear from management as the …
Palvella to Discuss Drug Pipeline at October 20 Conference Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) is preparing for a potential first-half 2027 U.S. launch of its experimental treatment for microcystic lymphatic malformations after completing its FDA application …
Palvella Advances Rare-Disease Drug Toward 2027 Launch Read More WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) appointed pediatric dermatologist James R. Treat as chief medical officer effective Dec. 21, putting a longtime clinical collaborator in charge of medical …
Palvella Names James Treat CMO as QTORIN Advances Toward Market Read More WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) Chief Executive Officer Wes Kaupinen will appear at two healthcare investor conferences in September, giving investors two near-term opportunities to hear from …
Palvella CEO to Pitch Rare-Disease Pipeline at Investor Meets Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) recently completed its U.S. application for approval of QTORIN™ rapamycin to treat microcystic lymphatic malformations, putting the Wayne-based biotechnology company on a …
ICYMI: Palvella Seeks FDA Approval for Rare-Disease Skin Therapy Read More WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) has completed its application for U.S. approval of QTORIN 3.9% rapamycin anhydrous gel to treat microcystic lymphatic malformations, moving the Wayne-based biotechnology …
Palvella Files FDA Bid for QTORIN Rapamycin in Rare Disease Read More WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) Chief Executive Officer Wes Kaupinen will address investors Wednesday at the Canaccord Genuity 46th Annual Growth Conference as the clinical-stage biotechnology company …
Palvella CEO to Address Investors at Canaccord Conference Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) began its rolling U.S. application for QTORIN rapamycin during the second quarter as higher clinical, manufacturing and regulatory spending more than doubled …
Palvella Advances FDA Filing as Drug Spending Lifts Loss Read More WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) Chief Scientific Officer Jeffrey Martini will address evidence gaps and regulatory barriers affecting drug repurposing at an Aug. 5 FDA public workshop …
Palvella Executive to Address FDA Drug Repurposing Barriers Read More WAYNE, PA — Palvella Therapeutics (Nasdaq: PVLA) has appointed biotechnology executive Matt Pauls to its board of directors as the company prepares for a potential U.S. launch of its lead …
Palvella Adds Rare-Disease Executive to Board Ahead of Launch Read More